Skip to main content
. 1999 Sep 28;96(20):11476–11481. doi: 10.1073/pnas.96.20.11476

Figure 2.

Figure 2

Effect of CTLA-4 blockade in tumor-bearing mice. Tumor-bearing mice or tumor-free mice received anti-HA TCR+ transgenic T cells and were treated with anti-CTLA-4 antibody (100 μg/day, i.p.) on days −1, 0, and +1 or received no treatment. On day +8 after T cell transfer, splenocytes were isolated as described in the text. (A) Phenotypic changes associated with antigen recognition in untreated and CTLA-4 treated tumor-bearing mice. Purified T cells were stained with Cy-Chrome-labeled anti-mouse CD4, biotinylated anti-TCR clonotype mAb 6.5 followed by phycoerythrin-labeled streptavidin and FITC-conjugated anti-mouse CD45RB. Live gating on CD4+ T cells was set, and 100,000 events were collected per sample. Forward light scatter (FSC) and the level of CD45RB expression were determined on clonotype+ T cells. The results are representative of two experiments with three mice per group. (B) Proliferative response to stimulation with HA peptide was determined as in Fig. 1. Data represent the mean + SE cpm per 100 clonotype+ T cells per well from three mice in each group.